» Authors » Nicki Panoskaltsis

Nicki Panoskaltsis

Explore the profile of Nicki Panoskaltsis including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 1169
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Gray M, de Janon A, Seeler M, Heller W, Panoskaltsis N, Mantalaris A, et al.
ACS Omega . 2025 Feb; 10(3):2628-2639. PMID: 39895718
Proteins can perform ideal therapeutic functions. However, their large size and significant surface hydrophilicity and charge prohibit them from reaching intracellular targets. These chemical features also render them poorly encapsulated...
2.
Klontzas M, Vernardis S, Batsali A, Papadogiannis F, Panoskaltsis N, Mantalaris A
J Funct Biomater . 2024 Dec; 15(12). PMID: 39728167
Stem cells have been widely used to produce artificial bone grafts. Nonetheless, the variability in the degree of stem cell differentiation is an inherent drawback of artificial graft development and...
3.
de Janon A, Mantalaris A, Panoskaltsis N
J Immunol . 2023 Mar; 210(7):895-904. PMID: 36947817
Hematoimmunopoiesis takes place in the adult human bone marrow (BM), which is composed of heterogeneous niches with complex architecture that enables tight regulation of homeostatic and stress responses. There is...
4.
Perl A, Hosono N, Montesinos P, Podoltsev N, Martinelli G, Panoskaltsis N, et al.
Blood Cancer J . 2022 May; 12(5):84. PMID: 35637252
The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared...
5.
Allenby M, Okutsu N, Brailey K, Guasch J, Zhang Q, Panoskaltsis N, et al.
Tissue Eng Part A . 2021 Jun; 28(1-2):38-53. PMID: 34130508
Cellular microenvironments provide stimuli, including paracrine and autocrine growth factors and physicochemical cues, which support efficient cell production unmatched by current biomanufacturing platforms. While three-dimensional (3D) culture systems aim to...
6.
Panoskaltsis N
Cancer Immunol Immunother . 2021 Jan; 70(4):887-892. PMID: 33416946
Cytokine release syndrome (CRS) is the result of massive pro-inflammatory cytokine release and imbalance in the absence of adequate immunomodulation from signals such as interleukin (IL)-10, resulting in ongoing inflammation,...
7.
McCarthy N, Stagg A, Price C, Mann E, Gellatly N, Al-Hassi H, et al.
Cancer Immunol Immunother . 2020 Oct; 70(4):1143-1153. PMID: 33048222
Following infusion of the anti-CD28 superagonist monoclonal antibody TGN1412, three of six previously healthy, young male recipients developed gastrointestinal irritability associated with increased expression of 'gut-homing' integrin β7 on peripheral...
8.
Panoskaltsis N, McCarthy N, Stagg A, Mummery C, Husni M, Arebi N, et al.
Cancer Immunol Immunother . 2020 Oct; 70(4):1127-1142. PMID: 33033851
Cytokine storm can result from cancer immunotherapy or certain infections, including COVID-19. Though short-term immune-related adverse events are routinely described, longer-term immune consequences and sequential immune monitoring are not as...
9.
Panoskaltsis N, McCarthy N, Knight S
Cancer Immunol Immunother . 2020 Aug; 70(4):1155-1160. PMID: 32862238
TGN1412, a superagonist monoclonal antibody targeting CD28, caused cytokine storm in six healthy volunteers in a first-in-man study in 2006. Despite clinical improvement and termination of the cytokine release syndrome...
10.
Klontzas M, Reakasame S, Silva R, Morais J, Vernardis S, Macfarlane R, et al.
Acta Biomater . 2019 Feb; 88:224-240. PMID: 30772514
Oxidized alginate hydrogels are appealing alternatives to natural alginate due to their favourable biodegradability profiles and capacity to self-crosslink with amine containing molecules facilitating functionalization with extracellular matrix cues, which...